London, May 14, 2026, 14:05 BST
Tate & Lyle PLC on Thursday said it’s talking with Ingredion, its U.S. competitor, about a possible all-cash buyout that would peg Tate & Lyle’s value around £2.74 billion ($3.70 billion). The current offer on the table: up to 615 pence for each share, with 595 pence in cash and the rest—20 pence—potentially coming by way of dividends.
Tate & Lyle has landed in the takeover spotlight barely a week before its full-year results. For investors battered by the squeeze on demand and margins, the move could offer an exit route. The bid ratchets up pressure on would-be buyers to spell out just how much extra they’re willing to pay for London-listed specialty ingredients names—especially as these firms shift away from less dynamic commodity businesses.
Shares jumped 52%, hitting 569.50 pence in early afternoon European trading. Still, that’s below the takeover bid—so the market clearly isn’t buying this as a done deal.
Tate & Lyle is set to post its FY2026 results on May 21. Chief Executive Nick Hampton and CFO Sarah Kuijlaars will be answering questions from analysts in London. The date isn’t perfect for everyone, but investors have been calling for details, particularly around the CP Kelco acquisition and management’s outlook on growth.
In February, Hampton put top-line growth at the top of Tate & Lyle’s agenda. Yet, pro forma revenue for the nine months ending Dec. 31 fell 3% at constant currency in the same update. The company is sticking with its projection for both revenue and EBITDA to edge down by a low-single-digit percent in 2026. EBITDA—earnings before interest, tax, depreciation and amortisation—remains the usual measure of operating profit before those items.
Still, no binding offer has surfaced. Tate & Lyle spelled it out: there’s no assurance Ingredion will proceed, and nothing is locked in on bid terms. The company released its statement independently, without any green light from Ingredion. As for the potential dividend, that’s conditional—board and shareholders still have to sign off.
According to the Takeover Panel’s disclosure table, Tate & Lyle’s offer period officially began at 13:07 BST on Thursday. Ingredion now faces a 17:00 BST cutoff on June 11 to declare a firm offer or step back. The deadline’s there to force a move, though the Panel retains the option to extend.
Ingredion isn’t coming at this as a private equity firm—it’s making its move from inside the sector. The Chicago-area company reported about $7.2 billion in net sales for 2025, selling ingredients derived from grains, fruits, vegetables, and other plants to clients in more than 120 countries.
Ingredion stands to bulk up its portfolio of sweeteners, fibre, starches, and mouthfeel enhancers—those texture-boosting additives—if it absorbs Tate & Lyle. For Tate & Lyle shareholders, the deal offers a shot at realizing value before anyone knows if the CP Kelco combination actually delivers.
Tate & Lyle closed its CP Kelco acquisition from J.M. Huber in November 2024, adding pectin, specialty gums, and more natural ingredients to its portfolio. Huber ended up with roughly 16% of Tate & Lyle through consideration shares—a notable chunk, and a formal offer here could put shareholders on alert.
Right now, it all comes down to whether Ingredion shifts from tentative interest to making a concrete offer. Unless that happens, Tate & Lyle shares are unlikely to trade like a standard food ingredients stock. For now, expect the price to move as a deal spread—each new twist stacked up against that 615p mark.
